Autolus Therapeutics (AUTL) announced the appointment of Robert Azelby to the Board of Directors. Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’s Board. Most recently, Azelby served as President and Chief Executive Officer of Eliem Therapeutics (ELYM).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AUTL:
- Autolus Therapeutics Announces Changes to its Board of Directors
- Autolus Therapeutics appoints Leiderman to board, Dhingra to step down
- Autolus Therapeutics presents clinical data updates at ASH Annual Meeting 2023
- Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
- Autolus Therapeutics submits BLA to U.S. FDA for obecabtagene autoleucel